{
  "source": "PA-Med-Nec-Ingrezza.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2137-10\nProgram Prior Authorization/Medical Necessity\nMedication Ingrezza® (valbenazine)\nP&T Approval Date 11/2017, 11/2018, 11/2019, 11/2020, 6/2021, 6/2022, 6/2023, 10/2023,\n4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background\nIngrezza is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the\ntreatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.1\n2. Coverage Criteriaa:\nA. Tardive Dyskinesia\n1. Initial Authorization\na. Ingrezza will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe tardive dyskinesia\n-AND-\n(2) One of the following:\n(a) Patient has persistent symptoms of tardive dyskinesia despite a trial of dose\nreduction, tapering, or discontinuation of the offending medication\n-OR-\n(b) Patient is not a candidate for a trial of dose reduction, tapering, or\ndiscontinuation of the offending medication\n-AND-\n(3) Prescribed by or in consultation with one of the following:\n(a) Neurologist\n(b) Psychiatrist\nAuthorization will be issued for 12 months.\n1. Reauthorization\na. Documentation of positive clinical response to Ingrezza therapy\n© 2025 UnitedHealthcare Services Inc.\n1\nAuthorization will be issued for 12 months.\nB. Chorea associated with Huntington’s disease\n1. Initial Authorization\na. Ingrezza will be approved based on both of the following criteria:\n(1) Diagnosis of chorea associated with Huntington's disease\n-AND-\n(2) Prescribed by or in consultation with one of the following:\n(a) Neurologist\n(b) Psychiatrist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Ingrezza therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional ",
    "apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Ingrezza [packate insert]. San Diego, CA: Neurocrine Biosciences, Inc.; February 2025.\n2. Hauser RA, Factor SA, Marder SR, et al. Kinect 3: A phase 3 randomized, double-blind,\nplacebo-controlled trial of valbenazine for tardive dyskinesia. American Journal of\nPsychiatry. May 2017. 174:5.\nProgram Prior Authorization/Medical Necessity - Ingrezza (valbenazine)\nChange Control\n11/2017 New program\n11/2018 Annual review. No changes to clinical coverage criteria. Updated\nreference.\n11/2019 Annual review. No changes to clinical coverage criteria. Updated\n© 2025 UnitedHealthcare Services Inc.\n2\nreference.\n11/2020 Annual review. Updated references.\n6/2021 Added Ingrezza exclusion statement. Removed continuation of therapy\nallowance from coverage criteria. Updated reference.\n6/2022 Annual review. No changes.\n6/2023 Annual review. Updated criteria to include extended-release Austedo\nformulation. Updated reference.\n10/2023 Added criteria for chorea associated with Huntington's disease.\nUpdated background and reference.\n4/2024 Removed notation that Ingrezza is typically excluded. Removed\nfailure, contraindication, or intolerance to Austedo/Austedo XR from\ncriteria.\n4/2025 Annual review with no change to clinical criteria. References updated.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}